Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial -

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial
Information type: Randomised controlled trials
Source: Lancet Public Health
Specialities: Cardiovascular system disorders
Summary
RCT of losmapimod, an oral p38 MAPK inhibitor vs. placebo in 535 NSTEMI patients, found safety outcomes did not differ between groups. Early suppression of inflammatory markers was similar in the groups by 12 weeks and infarct size was not reduced by treatment with losmapimod.
UKMi comment
A comment article suggests that these findings might, mark the beginning of intensive clinical exploration of protein kinases as therapeutic targets, which could eventually lead to these agents becoming part of routine cardiology therapy.
Related links: Comment